From the FDA Drug Label
CLINICAL PHARMACOLOGY Amphetamines are non-catecholamine, sympathomimetic amines with CNS stimulant activity. Pharmacokinetics ... Following administration of three 5 mg tablets, average maximal dextroamphetamine plasma concentrations (Cmax) of 36. 6 ng/mL were achieved at approximately 3 hours. Following administration of one 15 mg sustained-release capsule, maximal dextroamphetamine plasma concentrations were obtained approximately 8 hours after dosing.
The amphetamine formulation with a shorter duration than Mydayis is not explicitly stated in the provided drug label. However, based on the pharmacokinetics information, the immediate-release tablet formulation has a faster time to reach maximal plasma concentrations (approximately 3 hours) compared to the sustained-release capsule formulation (approximately 8 hours) 1.
- The plasma half-life (T1/2) of both formulations is approximately 12 hours.
- No direct comparison to Mydayis is provided in the label.
From the Research
Amphetamines with shorter duration than Mydayis include Adderall IR, Dexedrine, and Evekeo, which may be preferable for patients who need coverage for specific parts of the day or require more flexible dosing. Mydayis is a long-acting mixed amphetamine salt medication that lasts approximately 16 hours, while Adderall IR typically lasts 4-6 hours, Dexedrine 4-6 hours, and Evekeo 4-6 hours. These shorter-acting options can be taken multiple times throughout the day as needed, though this requires more frequent dosing. The shorter duration results from different delivery mechanisms - immediate release formulations allow the medication to be absorbed quickly rather than using the triple-bead technology of Mydayis that extends release over many hours.
- Key considerations for choosing between these options include the patient's specific needs, potential side effects, and the risk of abuse or dependence, as highlighted in studies such as 2 which notes the potential for amphetamines to increase blood pressure and heart rate.
- Patients should be aware that shorter-acting stimulants may cause more noticeable peaks and valleys in symptom control compared to long-acting formulations, and may require multiple doses throughout the day to maintain effectiveness, as discussed in 3 which reviews the dextroamphetamine transdermal system for the treatment of ADHD.
- The most recent and highest quality study, 2, provides high-certainty evidence that daily oral amphetamines increase blood pressure, heart rate, and withdrawals due to adverse effects, which should be taken into account when prescribing these medications.
- Overall, the choice of amphetamine medication should be based on a careful consideration of the patient's individual needs and medical history, as well as the potential benefits and risks of each option, as discussed in 4 and 5.